Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is VX15 that is in Phase Ib/II clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, osteosarcoma, and melanoma; and Phase II clinical trials for the treatment of Huntington's disease. The company's preclinical development products include VX5, a human antibody to CXCL13, a molecule that regulates the formation of immune tissues, for the treatment of MS and other autoimmune disorders; and VX25 is an investigational and bi-specific molecule for the therapeutic application of Natural Killer T cell stimulation for cancer immunotherapy. Vaccinex, Inc. was founded in 2001 and is headquartered in Rochester, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone585-271-2700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$720,000.00
Profitability
Miscellaneous
Employees42
Next Earnings Date6/12/2019 (Estimated)
OptionableNot Optionable
Vaccinex (NASDAQ:VCNX) Frequently Asked Questions
What is Vaccinex's stock symbol?
Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."
How were Vaccinex's earnings last quarter?
Vaccinex Inc (NASDAQ:VCNX) issued its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.93) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.29. The company had revenue of $0.20 million for the quarter. View Vaccinex's Earnings History.
When is Vaccinex's next earnings date?
What price target have analysts set for VCNX?
3 Wall Street analysts have issued 1-year price objectives for Vaccinex's shares. Their predictions range from $22.00 to $22.00. On average, they expect Vaccinex's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 347.2% from the stock's current price. View Analyst Price Targets for Vaccinex.
What is the consensus analysts' recommendation for Vaccinex?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vaccinex.
Has Vaccinex been receiving favorable news coverage?
Media headlines about VCNX stock have been trending negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vaccinex earned a coverage optimism score of -2.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the next several days.
Who are some of Vaccinex's key competitors?
Some companies that are related to Vaccinex include Galectin Therapeutics (GALT), Poxel (PXXLF), MEI Pharma (MEIP), Adamas Pharmaceuticals (ADMS), Mersana Therapeutics (MRSN), Axovant Sciences (AXGT), CELYAD SA/ADR (CYAD), Marinus Pharmaceuticals (MRNS), Recro Pharma (REPH), LifeVantage (LFVN), Proteostasis Therapeutics (PTI), Aldeyra Therapeutics (ALDX), Ardelyx (ARDX), Synlogic (SYBX) and Molecular Templates (MTEM).
What other stocks do shareholders of Vaccinex own?
Who are Vaccinex's key executives?
Vaccinex's management team includes the folowing people:
- Dr. Maurice Zauderer, Co-Founder, CEO, Pres & Director (Age 74)
- Mr. Raymond E. Watkins, Sr. VP & COO (Age 61)
- Dr. Ernest S. Smith, Sr. VP of Research & Chief Scientific Officer (Age 47)
- Dr. Deepak M. Sahasrabudhe, Co-Founder, Sr. Mang. of Laboratory Operations & Safety and Scientific & Clinical Advisor
- Mr. Scott E. Royer C.F.A., M.B.A., Chief Financial Officer (Age 45)
When did Vaccinex IPO?
(VCNX) raised $45 million in an initial public offering on Thursday, August 9th 2018. The company issued 3,300,000 shares at $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.
When did Vaccinex's lock-up period expire?
Vaccinex's lock-up period expired on Tuesday, February 5th. Vaccinex had issued 3,333,334 shares in its initial public offering on August 9th. The total size of the offering was $40,000,008 based on an initial share price of $12.00. Since the expiration of Vaccinex's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Who are Vaccinex's major shareholders?
Vaccinex's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (0.64%) and Telemetry Investments L.L.C. (0.13%). Company insiders that own Vaccinex stock include Albert Friedberg and Scott E Royer. View Institutional Ownership Trends for Vaccinex.
Which institutional investors are selling Vaccinex stock?
Which institutional investors are buying Vaccinex stock?
VCNX stock was bought by a variety of institutional investors in the last quarter, including Telemetry Investments L.L.C.. Company insiders that have bought Vaccinex stock in the last two years include Albert Friedberg and Scott E Royer. View Insider Buying and Selling for Vaccinex.
How do I buy shares of Vaccinex?
Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vaccinex's stock price today?
One share of VCNX stock can currently be purchased for approximately $4.9190.
How big of a company is Vaccinex?
Vaccinex has a market capitalization of $56.47 million and generates $720,000.00 in revenue each year. The company earns $-29,520,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis. Vaccinex employs 42 workers across the globe.
What is Vaccinex's official website?
How can I contact Vaccinex?
Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]
MarketBeat Community Rating for Vaccinex (NASDAQ VCNX)
MarketBeat's community ratings are surveys of what our community members think about Vaccinex and other stocks. Vote "Outperform" if you believe VCNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
